{{cart_num}}
My CartCAS：65836-72-8
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 65836-72-8 |
| Name | (2-chloro-N) - 3, 4-dimethoxybenzyl acetamide |
| Molecular Formula | C11H14ClNO3 |
| Molecular Weight | 243.69 |
| Solubility | Soluble in DMSO ≥5mg/mL(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 604-604-1 |
| MDL | MFCD01733639 |
| SMILES | O=C(NCC1=CC=C(OC)C(OC)=C1)CCl |
| InChIKey | CETPWRGZGWGPSV-UHFFFAOYSA-N |
| InChI | InChI=1S/C11H14ClNO3/c1-15-9-4-3-8(5-10(9)16-2)7-13-11(14)6-12/h3-5H,6-7H2,1-2H3,(H,13,14) |
| PubChem CID | 2392259 |
| Target Point | UBA5 |
| Passage | Ubiquitin |
| Background | (2-chloro-N)-3,4-dimethoxybenzyl acetamide is a selective inhibitor of ubiquitin-like modifier activating enzyme 5 (UBA5). |
| Biological Activity | DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM.[1] |
| IC50 | IC50: 430μM(UBA5);90μM(PaCa2 cells);30μM(Panc1 cells)[1] |
| In Vitro | Ubiquitin-like modifier activating enzyme 5(UBA5)is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5，thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC50s of 90 and 30 μM，respectively[1]. |
| In Vivo | DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity[1]. |
| Cell Experiment | PaCa2 and Panc1 cells are treated with 0-1000 μM DKM 2-93 for 48 hours. Cell viability is assessed by Hoescht stain[1]. |
| Animal Experiment | Mice: Mice are subcutaneously injected with PaCa2 cells to initiate the tumor xenograft study and treatments of mice are initiated with vehicle or DKM 2-93(50 mg/kg ip，once per day)three days after injection of cancer cells[1]. |
| Data Literature Source | [1]. Roberts AM，et al. Chemoproteomic Screening of Covalent Ligands Reveals UBA5 As a Novel Pancreatic Cancer Target. ACS Chem Biol. 2017 Apr 21;12(4):899-904. |
| Unit | Bottle |
| Specification | 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Manual Download
